Mark G. Fromhold, Ph.D., Vice President, Manufacturing & Business Development, Koronis Pharmaceuticals

PodcastsResourcesDrug therapyHIVLentivirusMedicine, Diagnosis, and TherapeuticsMicrobiologyMicroorganismsRetroviridaeRNA virusTherapeuticsVirus
Previous articleMarketing Innovations for Biotechs to Increase Revenues
Next articleScientists Generate Pneumococcal Serotype 3 Vaccine Using Synthetic Toxin Gene